During the past decade, Carle Cancer Institute Normal conducted 5 clinical trials. In the 10-year time frame, 5 clinical trials started and 30 clinical trials were completed, i.e. on average, 600% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 8 clinical trials were completed. i.e. 200% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Carle Cancer Institute Normal" #1 sponsor was "National Cancer Institute (NCI)" with 35 trials, followed by "GOG Foundation" with 3 trials sponsored, "Alliance for Clinical Trials in Oncology" with 1 trials sponsored, "ECOG-ACRIN Cancer Research Group" with 1 trials sponsored and "Eastern Cooperative Oncology Group" with 1 trials sponsored. Other sponsors include -1 different institutions and companies that sponsored additional 9 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Carle Cancer Institute Normal" #1 collaborator was "National Cancer Institute (NCI)" with 9 trials as a collaborator, "NRG Oncology" with 8 trials as a collaborator, "Cancer and Leukemia Group B" with 3 trials as a collaborator, "NCIC Clinical Trials Group" with 3 trials as a collaborator and "North Central Cancer Treatment Group" with 3 trials as a collaborator. Other collaborators include 5 different institutions and companies that were collaborators in the rest 12 trials.

According to Clinical.Site data, the most researched conditions in "Carle Cancer Institute Normal" are "Recurrent Breast Carcinoma" (3 trials), "Stage IIA Fallopian Tube Cancer AJCC v6 and v7" (3 trials), "Stage IIA Ovarian Cancer AJCC V6 and v7" (3 trials), "Stage IIB Fallopian Tube Cancer AJCC v6 and v7" (3 trials) and "Stage IIB Ovarian Cancer AJCC v6 and v7" (3 trials). Many other conditions were trialed in "Carle Cancer Institute Normal" in a lesser frequency.

Most popular intervention types in "Carle Cancer Institute Normal" are "Other" (36 trials), "Drug" (35 trials), "Biological" (24 trials), "Radiation" (7 trials) and "Procedure" (3 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (29 trials), "Quality-of-Life Assessment" (13 trials), "Bevacizumab" (12 trials), "Paclitaxel" (10 trials) and "Cisplatin" (7 trials). Other intervention names were less common.

The vast majority of trials in "Carle Cancer Institute Normal" are 31 trials for "All" genders, 13 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Carle Cancer Institute Normal". undefined are not yet recruiting, 6 are recruiting, 32 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 7 completed trials in Carle Cancer Institute Normal, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Carle Cancer Institute Normal, 1 "Phase 1" clinical trials were conducted, 14 "Phase 2" clinical trials and 28 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 2 trials that are defined as “Not Applicable".